CJC-1295 is a tetrasubstituted peptide of 29 amino acid length, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It was invented by ConjuChem, a Canadian biotechnology company. Purity: 98% (HPLC). CJC-1295 is sold in 2mg vials.
Out of stock
Molecular Formula : C165H269N47O46
Molecular Weight :3647.15
CAS No. : 863288-34-0
For RESEARCH PURPOSES ONLY
CJC-1295,a maleimido derivative of hGRF(1-29), is a synthetic human GHRH analog that selectively and covalently binds to endogenous albumin after subcutaneous administration, thereby extending its half-life and duration of action.
One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.
CJC-1295 is an analogue of GHRH with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide. These substitutions are key in increasing the overall half life of CJC-1295.
Various experiments have been conducted to test the effectiveness of CJC-1295. The Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection. The mean half life was 5.8-8.1 days and after multiple doses mean IGF-1 levels remained above baseline for up to 28 days following. No serious adverse reactions were reported in any group participating in this study. This peptide has the ability to stimulate growth hormone very significantly.
THIS PRODUCT IS NOT FOR HUMAN USE NOR IS IT INTENDED TO
TREAT PREVENT OR CURE ANY DISEASES. canadapeptides WILL
DENY ANY ORDER IF WE FEEL IT WILL NOT BE USED TO THE
CONDITIONS SPECIFIED IN OUR DISCLAIMER WHICH IS AGREED
UPON BEFORE ENTERING THE SITE.